
James H Mcmahon

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7880019/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Activation of HIV Transcription with Short-Course Vorinostat in HIV-Infected Patients on Suppressive Antiretroviral Therapy. PLoS Pathogens, 2014, 10, e1004473.	2.1	437
2	Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials. Lancet, The, 2019, 393, 143-155.	6.3	265
3	Rapid generation of durable B cell memory to SARS-CoV-2 spike and nucleocapsid proteins in COVID-19 and convalescence. Science Immunology, 2020, 5, .	5.6	244
4	Short-term administration of disulfiram for reversal of latent HIV infection: a phase 2 dose-escalation study. Lancet HIV,the, 2015, 2, e520-e529.	2.1	213
5	Pharmacy Adherence Measures to Assess Adherence to Antiretroviral Therapy: Review of the Literature and Implications for Treatment Monitoring. Clinical Infectious Diseases, 2011, 52, 493-506.	2.9	139
6	BET inhibition blocks inflammation-induced cardiac dysfunction and SARS-CoV-2 infection. Cell, 2021, 184, 2167-2182.e22.	13.5	131
7	Long-term Virological Outcomes of First-Line Antiretroviral Therapy for HIV-1 in Low- and Middle-Income Countries: A Systematic Review and Meta-analysis. Clinical Infectious Diseases, 2015, 61, 1453-1461.	2.9	129
8	Monkeypox infection presenting as genital rash, Australia, May 2022. Eurosurveillance, 2022, 27, .	3.9	116
9	Viral suppression after 12 months of antiretroviral therapy in low- and middle-income countries: a systematic review. Bulletin of the World Health Organization, 2013, 91, 377-385E.	1.5	115
10	Integrated immune dynamics define correlates of COVID-19 severity and antibody responses. Cell Reports Medicine, 2021, 2, 100208.	3.3	115
11	Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial. Lancet HIV,the, 2018, 5, e211-e220.	2.1	108
12	Barriers and strategies to achieve a cure for HIV. Lancet HIV,the, 2018, 5, e317-e328.	2.1	99
13	The HIV care cascade: a systematic review of data sources, methodology and comparability. Journal of the International AIDS Society, 2015, 18, 20634.	1.2	92
14	Broad activation of latent HIV-1 in vivo. Nature Communications, 2016, 7, 12731.	5.8	65
15	HIV Drug Resistance Early Warning Indicators in Cohorts of Individuals Starting Antiretroviral Therapy Between 2004 and 2009: World Health Organization Global Report From 50 Countries. Clinical Infectious Diseases, 2012, 54, S280-S289.	2.9	62
16	Concomitant medication polypharmacy, interactions and imperfect adherence are common in Australian adults on suppressive antiretroviral therapy. Aids, 2018, 32, 35-48.	1.0	60
17	Poverty, Hunger, Education, and Residential Status Impact Survival in HIV. AIDS and Behavior, 2011, 15, 1503-1511.	1.4	55
18	Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 96-week results of a randomised, double-blind, non-inferiority, phase 3 trial. Lancet HIV,the, 2020, 7, e16-e26.	2.1	53

#	Article	IF	CITATIONS
19	Repeated Assessments of Food Security Predict CD4 Change in the Setting of Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 58, 60-63.	0.9	46
20	Clinical care of pregnant and postpartum women with COVIDâ€19: Living recommendations from the National COVIDâ€19 Clinical Evidence Taskforce. Australian and New Zealand Journal of Obstetrics and Gynaecology, 2020, 60, 840-851.	0.4	36
21	Diverse effects of interferon alpha on the establishment and reversal of HIV latency. PLoS Pathogens, 2020, 16, e1008151.	2.1	36
22	Effects of Physical Tracing on Estimates of Loss to Follow-Up, Mortality and Retention in Low and Middle Income Country Antiretroviral Therapy Programs: A Systematic Review. PLoS ONE, 2013, 8, e56047.	1.1	35
23	The effect of antiretroviral intensification with dolutegravir on residual virus replication in HIV-infected individuals: a randomised, placebo-controlled, double-blind trial. Lancet HIV,the, 2018, 5, e221-e230.	2.1	34
24	Thrombospondin-I is a critical modulator in non-alcoholic steatohepatitis (NASH). PLoS ONE, 2019, 14, e0226854.	1.1	34
25	Clinical trials of antiretroviral treatment interruption in HIV-infected individuals. Aids, 2019, 33, 773-791.	1.0	34
26	Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trial. Lancet HIV,the, 2017, 4, e486-e494.	2.1	31
27	Population Pharmacokinetics and Pharmacodynamics of Disulfiram on Inducing Latent HIVâ€1 Transcription in a Phase IIb Trial. Clinical Pharmacology and Therapeutics, 2019, 105, 692-702.	2.3	29
28	Is hospital-in-the-home (HITH) treatment of bacterial endocarditis safe and effective?. Scandinavian Journal of Infectious Diseases, 2008, 40, 40-43.	1.5	27
29	Experiences and expectations of participants completing an HIV cure focused clinical trial. Aids, 2015, 29, 248-250.	1.0	27
30	Perspectives on Analytical Treatment Interruptions in People Living with HIV and Their Health Care Providers in the Landscape of HIV Cure-Focused Studies. AIDS Research and Human Retroviruses, 2020, 36, 260-267.	0.5	24
31	Multiply spliced HIV RNA is a predictive measure of virus production ex vivo and in vivo following reversal of HIV latency. EBioMedicine, 2021, 65, 103241.	2.7	24
32	The Impact of the COVID-19 Pandemic on People Living with HIV in Victoria, Australia. AIDS Research and Human Retroviruses, 2021, 37, 322-328.	0.5	21
33	Clinic Network Collaboration and Patient Tracing to Maximize Retention in HIV Care. PLoS ONE, 2015, 10, e0127726.	1.1	21
34	SARS-CoV-2 infection results in immune responses in the respiratory tract and peripheral blood that suggest mechanisms of disease severity. Nature Communications, 2022, 13, 2774.	5.8	21
35	Pharmacy and Self-Report Adherence Measures to Predict Virological Outcomes for Patients on Free Antiretroviral Therapy in Tamil Nadu, India. AIDS and Behavior, 2013, 17, 2253-2259.	1.4	17
36	Time from HIV diagnosis to commencement of antiretroviral therapy as an indicator to supplement the HIV cascade: Dramatic fall from 2011 to 2015. PLoS ONE, 2017, 12, e0177634.	1.1	17

#	Article	IF	CITATIONS
37	The impact of immune checkpoint therapy on the latent reservoir in HIV-infected individuals with cancer on antiretroviral therapy. Aids, 2021, 35, 1631-1636.	1.0	16
38	Combination Immune Checkpoint Blockade Enhances IL-2 and CD107a Production from HIV-Specific T Cells Ex Vivo in People Living with HIV on Antiretroviral Therapy. Journal of Immunology, 2022, 208, 54-62.	0.4	16
39	90-90-90: how do we get there?. Lancet HIV,the, 2014, 1, e10-e11.	2.1	14
40	Torsades de pointes in a patient receiving fluconazole for cerebral cryptococcosis. American Journal of Health-System Pharmacy, 2008, 65, 619-623.	0.5	13
41	Post-treatment control in an adult with perinatally acquired HIV following cessation of antiretroviral therapy. Aids, 2017, 31, 1344-1346.	1.0	13
42	A clinical trial of non-invasive imaging with an anti-HIV antibody labelled with copper-64 in people living with HIV and uninfected controls. EBioMedicine, 2021, 65, 103252.	2.7	12
43	Identification of 5-Substituted 2-Acylaminothiazoles That Activate Tat-Mediated Transcription in HIV-1 Latency Models. Journal of Medicinal Chemistry, 2019, 62, 5148-5175.	2.9	11
44	The Australasian COVID-19 Trial (ASCOT) to assess clinical outcomes in hospitalised patients with SARS-CoV-2 infection (COVID-19) treated with lopinavir/ritonavir and/or hydroxychloroquine compared to standard of care: A structured summary of a study protocol for a randomised controlled trial. Trials, 2020, 21, 646.	0.7	11
45	Impact of alemtuzumab on HIV persistence in an HIV-infected individual on antiretroviral therapy with Sezary syndrome. Aids, 2017, 31, 1839-1845.	1.0	10
46	Yoghurt consumption and damaged colonic mucosa: A case of Lactococcus lactis liver abscess in an immunocompetent patient. Scandinavian Journal of Infectious Diseases, 2006, 38, 739-741.	1.5	9
47	Risk factors for mortality during antiretroviral therapy in older populations in resourceâ€limited settings. Journal of the International AIDS Society, 2016, 19, 20665.	1.2	9
48	No adverse safety or virological changes 2 years following vorinostat in HIV-infected individuals on antiretroviral therapy. Aids, 2017, 31, 1137-1141.	1.0	9
49	Acceptability, motivation and the prospect of cure for people living with HIV and their healthcare providers in HIV cure-focused treatment interruption studies. AIDS Research and Therapy, 2020, 17, 65.	0.7	9
50	Leveraging the advances in HIV for COVID-19. Lancet, The, 2020, 396, 943-944.	6.3	8
51	Paying the price in an era of HIV treatment as prevention: a retrospective study of the cost burden of HIV treatment for people living with HIV in Victoria, Australia. Sexual Health, 2015, 12, 34.	0.4	7
52	The RNA-Binding Proteins SRP14 and HMGB3 Control HIV-1 Tat mRNA Processing and Translation During HIV-1 Latency. Frontiers in Genetics, 2021, 12, 680725.	1.1	7
53	Neurotoxicity with high-dose disulfiram and vorinostat used for HIV latency reversal. Aids, 2022, 36, 75-82.	1.0	7
54	An adaptive randomised placebo controlled phase II trial of antivirals for COVID-19 infection (VIRCO): A structured summary of a study protocol for a randomised controlled trial. Trials, 2020, 21, 847.	0.7	6

#	Article	IF	CITATIONS
55	Cutting Edge: SARS-CoV-2 Infection Induces Robust Germinal Center Activity in the Human Tonsil. Journal of Immunology, 2022, , ji2101199.	0.4	6
56	Routine versus Targeted Viral Load Strategy among Patients Starting Antiretroviral in Hanoi, Vietnam. Journal of the International AIDS Society, 2019, 22, e25258.	1.2	5
57	A New Method for Estimating the Incidence of Infectious Diseases. American Journal of Epidemiology, 2021, 190, 1386-1395.	1.6	5
58	Bringing evidence from press release to the clinic in the era of COVID-19. Journal of Antimicrobial Chemotherapy, 2021, 76, 547-549.	1.3	5
59	Integrase-resistant HIV in an antiretroviral-naive patient in Australia. Aids, 2017, 31, 598-600.	1.0	4
60	Improvements in transition times through the HIV cascade of care among gay and bisexual men with a new HIV diagnosis in New South Wales and Victoria, Australia (2012–19): a longitudinal cohort study. Lancet HIV,the, 2021, 8, e623-e632.	2.1	4
61	Disseminated nocardiosis with adrenal abscess masquerading as metastatic adrenal cancer in an immunocompetent adult. ANZ Journal of Surgery, 2021, 91, E396-E398.	0.3	4
62	Histologic, immunohistochemical, microbiological, molecular biological and ultrastructural characterization of pulmonary tularemia. Pathology Research and Practice, 2011, 207, 63-66.	1.0	3
63	Targets for intervention to improve virological outcomes for patients receiving free antiretroviral therapy in Tamil Nadu, India. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2014, 26, 559-566.	0.6	3
64	Risk factors for unstructured treatment interruptions and association with survival in low to middle income countries. AIDS Research and Therapy, 2016, 13, 25.	0.7	3
65	Treatment of disseminated histoplasmosis in advanced HIV using itraconazole with increased bioavailability. International Journal of STD and AIDS, 2018, 29, 1448-1450.	0.5	3
66	Viral, inflammatory, and reservoir characteristics of posttreatment controllers. Current Opinion in HIV and AIDS, 2021, 16, 249-256.	1.5	3
67	Updated Australian guidance for health care providers about "undetectable = untransmittable―for HIV. Medical Journal of Australia, 2021, 215, 201.	0.8	3
68	Detection of Chimeric Cellular: HIV mRNAs Generated Through Aberrant Splicing in HIV-1 Latently Infected Resting CD4+ T Cells. Frontiers in Cellular and Infection Microbiology, 2022, 12, 855290.	1.8	3
69	Balancing Statistical Power and Risk in HIV Cure Clinical Trial Design. Journal of Infectious Diseases, 2022, 226, 236-245.	1.9	2
70	Recruiting people with HIV to an online self-management support randomised controlled trial: barriers and facilitators. Sexual Health, 2019, 16, 340.	0.4	1
71	Is it time for injectable antiretroviral therapy for HIV?. Lancet, The, 2020, 396, 1944-1946.	6.3	1
72	Successful treatment of disseminated Mycobacterium simiae infection in a patient with advanced HIV. Aids, 2021, 35, 157-158.	1.0	1

5

#	Article	IF	CITATIONS
73	IgG4-related disease masquerading as a fungating groin lesion in a patient with HIV and incomplete immune reconstitution. Aids, 2021, 35, 706-707.	1.0	1
74	Interrupting antiretroviral therapy in HIV cure trials during COVID-19: Adaptation to low transmission settings. Journal of Virus Eradication, 2021, 7, 100032.	0.3	1
75	Exploring sentinel conditions and the accrual sequence of multiple long-term condition multimorbidity using birth cohort and primary care data: an exploratory retrospective cohort study. Lancet, The, 2021, 398, S54.	6.3	1
76	Less frequent CD4 monitoring in virologically suppressed HIV. Lancet HIV,the, 2017, 4, e233-e234.	2.1	0
77	Early Outpatient Treatment of SARS-CoV-2 (COVID-19): A Comment. American Journal of Medicine, 2021, 134, e220-e221.	0.6	0
78	Acceptability of Injectable Antiretroviral Therapy in Australian Travelers With HIV. Journal of Acquired Immune Deficiency Syndromes (1999), 2021, 86, e13-e15.	0.9	0